Envision Technologies BV’s latest artificial intelligence (AI)-powered smart glasses for the blind and visually impaired are designed to help with reading, scanning faces and navigating everyday tasks. This visual assistant was introduced at California State University Northridge (CSUN) 2022 Assistive Technology Conference. Envision has updated its AI-based platform and ecosystem with improved optical character recognition (OCR) and better text recognition with contextual intelligence.
After three years of clinical research, Royal Philips NV said its Tack (4-F) endovascular system has shown promising results for arterial dissection repair following balloon angioplasty in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. The data was collected from a 36-month follow-up in the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee clinical trial.
Onward Medical NV reported initial patient enrollment in its Hemon early feasibility study and first-in-human trial of its ARC implantable pulse generator. The study will examine stabilization of hemodynamic function in patients with a spinal cord injury. It is taking place at Lausanne University Hospital (CHUV). “Implanting into a human for the first time is an important step forward for our neurostimulation technology, designed to help refine and implement epidural stimulation therapy in patients with spinal cord injury,” Dave Marver, CEO of Onward, told BioWorld.
Just three months after raising $10 million from its IPO on the Paris Euronext Growth market, SMAIO SA (Software Machines and Adaptive Implants in Orthopedics) obtained U.S. FDA 510(k) clearance for its Balance Analyzer 3D surgery planning software and for its patient-specific union rods. This spinal realignment planning software uses medical imaging of the patient’s spine in an upright static position.
Diabeloop SA has just closed a series C funding round, securing $73 million to ramp global expansion for its DBL1 integrated smart system for patients with type 1 diabetes. “This will allow us to boost commercial roll-out and continue pursuing our growth strategy into Europe, the U.S. and Asia,” Erik Huneker, CEO of Diabeloop, told BioWorld.
Mittelstand Santé, a new Franco-German health-tech alliance, has just published its first compilation of feedback from executives of French and German health care companies relating to the COVID pandemic. The French contingent is developing proposals aimed at strengthening the resilience of European health care manufacturing.
Wandercraft SAS unveiled Atalante X, its next-generation autonomous exoskeleton based on the concept of dynamic robotics. This self-balancing, walking exoskeleton, hands-free and without crutches, helps patients at all stages of physical therapy for learning to walk again by replicating a natural walking pattern. “We are responding to a major demand for physical therapy for learning to walk again while relieving the work of clinical staff,” Matthieu Masselin, CEO and co-founder of Wandercraft, told BioWorld.
Medi-Globe GmbH, in conjunction with the Institut Hospitalo-Universitaire (IHU) in Strasbourg, France, is developing new artificial intelligence (AI) software for the detection of pancreatic disease. The Rohrdorf Germany-based company just completed a first-in-human trial of this AI tool during an endoscopic ultrasound examination performed at the Institute of Image-Guided Surgery at IHU.
Less than three years after unveiling the first Sonovein device, Theraclion SA is launching its CE-marked, third-generation platform, Sonovein HD. This represents a new generation of robotics platform for noninvasive treatment of varicose veins. The new version integrates the acquisition and analysis of technical data during the procedure.
Medtech Europe, the European trade association for the medical technology industry covering diagnostics, medical devices and digital health, has just adopted a new code of ethical business practice.
